Go Pro
NYSE:DHR

Danaher Q3 2026 Earnings Report

Danaher logo
$216.12 +4.31 (+2.03%)
Closing price 09/21/2026 03:58 PM Eastern
Extended Trading
$215.68 -0.44 (-0.20%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher EPS Results

Actual EPS
N/A
Consensus EPS
$1.91
Beat/Miss
N/A
One Year Ago EPS
N/A

Danaher Revenue Results

Actual Revenue
N/A
Expected Revenue
$6.55 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Danaher Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Tuesday, October 20, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Danaher Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Danaher declares $0.40 dividend
Danaher Announces Quarterly Dividend
See More Danaher Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Danaher? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Danaher and other key companies, straight to your email.

About Danaher

Danaher (NYSE:DHR) (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products. Danaher also owns Pall and Abcam, among other specialized life sciences businesses.

Founded in 1969 by Steven and Mitchell Rales, Danaher takes its name from the Danaher Creek in western Montana. The company has expanded through acquisitions and operational improvements and serves customers in North America, Europe, Asia and other international markets. Rainer M. Blair has served as Danaher’s president and chief executive officer since 2020.

View Danaher Profile